All In Biotech

Drug Trial Radar · NCT01098357

Comparative Study of 3 Dose Regimens of BioChaperone to Becaplermin Gel for the Treatment of Diabetic Foot Ulcer

A Phase I/II, Multicentre, Randomised, Controlled, and Open-label Trial Comparing the Efficacy and Safety of Three Dose Regimens of BioChaperone PDGF-BB to Becaplermin Gel for the Treatment of Diabetic Foot Ulcer

Last checked: Nov 20, 2026Latest source record: Dec 15, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 192 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

192

Actual

Start

Jun 2010

Primary completion

Feb 2011

Study completion Sep 2011

Sponsor

Lead sponsor
Virchow GroupIndustry
Sponsor type
Industry
Collaborators
Adocia
First posted
Apr 2, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, active-control, multicentre, parallel group, randomised and dose-finding efficacy and safety study. Compare the efficacy and safety of BioChaperone PDGF-BB applied at 12.5 µg/cm² every two days for up to 20 weeks to becaplermin gel (Regranex® Gel 0.01%) applied daily for up to 20 weeks for the treatment of neuropathic diabetic foot ulcer. Assess the effect of a double dose of BioChaperone PDGF-BB (25 µg/cm²) applied every two days for up to 20 weeks.

Conditions

  • Diabetic Foot Ulcers

Interventions

  • Biochaperone PDGF-BB Low doseDrug

    BioChaperone PDGF-BB low dose is applied as a spray every two days at the dose of 12.5 µg/cm2 for up to 20 weeks

  • Biochaperone PDGF-BB High doseDrug

    BioChaperone PDGF-BB high dose is applied as a spray every two days at the dose of 25 µg/cm2 for up to 20 weeks

  • RegranexDrug

    Regranex gel is applied once daily at the dose of 6.25 µg/cm2 for up to 20 weeks

  • Biochaperone PDGF-BB Very Low DoseDrug

    BioChaperone PDGF-BB Very Low Dose sprayed on the wound every two days (e.g., Mondays, Wednesdays and Fridays) for 20 weeks or until complete wound healing, at the dose of 4 µg/cm²/application

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of complete wound closureTime frame: 20 WEEKS

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Vijay Vachharajani Memorial

    Rajkot, Gujarat, India

  • Jain Institute of Vascular sciences

    Bangalore, Karnataka, India

  • Karnataka Institute of Diabetology

    Bangalore, Karnataka, India

  • Lakeshore Hospital & Research Centre Ltd

    Kochi, Kerala, India

  • Joshi Hospital , Maharashra Medical Foundation

    Pune, Maharashtra, India

  • M.V. Hospital for Diabetes

    Chennai, Tamil Nadu, India

  • S.K. Diabetes Research & Education Centre

    Kolkata, West Bengal, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.